After Market Report - HEB - Hemispherx Holds Annual Meeting, Low Turnout - Sourced WhisperFromWallStreet.com

After Market Report - HEB - Hemispherx Holds Annual Meeting, Low Turnout - Sourced WhisperFromWallStreet.com

HEMISPHERX BIOPHARMA,HEB

2.07 Up 0.01 (0.49%) 4:58PM ET

Hemispherx Biopharma (NYSE: HEB) held its annual meeting and below are some facts regarding the meeting. There was an extremely low turnout at Hemispherx Biopharma annual meeting. HEB believes that this was due to the fact that more than 40% of its outstanding shares are held outside the United States. Most of these shares are held at European banks that do not participate in the proxies of American companies. Even with the quorum lowered to 40% for the meeting, only approximately 40.34% of the outstanding shares entitled to vote were represented in person or by proxy. At the meeting, each of the five nominees for director named in the Company's proxy statementwas elected to a one-year term, the selection of McGladrey & Pullen, LLP as independent auditors for the fiscal year ending December 31, 2009 was ratified and the adoption of the Company's 2009 Equity Incentive Plan was approved.     

Last Trade:      2.06                
Day's Range:    2.00 - 2.22    
52wk Range:    0.25 - 4.54    
Volume:          3,787,941

ABOUT

Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders. The companys products include Alferon N Injection for the treatment of genital warts; and Ampligen, an experimental drug that is in human clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, HIV, renal cell carcinoma, and malignant melanoma. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of viral diseases and disorders of the immune system. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
---

WhisperfromWallStreet.com has a proven track record in picking winning stocks.  While neither we nor anyone can offer a guarantee, we scan countless stocks on a daily basis to seek out those that have the greatest opportunity for gain.  When we find these stocks, we immediately send an alert to our membership.  Please feel free to track our results by joining our newsletter free.  So far in 2009 we have sent over 40 alerts to our members with an average gain of over 80%.

Join our stock alert service free.

If you're an investor and interested in knowing which penny stocks are getting ready to run, sign up for our penny alerts at http://whisperfromwallstreet.com/

During 2009 we have sent out over 40 stock alerts resulting in an over 80% price gain.  Sign up now FREE to track our results.

---

Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php

IMPORTANT NOTE: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.  This press release should not be construed as a solicitation to buy or sell any particular stock or security.  Neither WhisperfromWallstreet, nor any of its affiliates are registered investment advisors or broker dealers.